lot, up just that through making, are front. Amol. financial progress that's going we Thanks website. we the and every go describe on occurring our I'll on and to Today strategic a that's about are agenda the Basically,
with neurology up addition, the for the just In some commentary stacks specific the goals and technologies results real important end healthcare. the interacting provide describing made and I'd that transforming how way we've being very QX set like but around the then remarks year, regarding to I'll versus my are that's progress our
with start just for quarter. me Let highlights the the
You the half, had first XX%. that's revenue XX% for growth, which,
supporting in development have ever a the us of investors continued graph, where side the we right-hand going As see of us efforts. since our helping and on you can business we've lot public,
drugs pharma that to get them approved right our achieve. what technologies biotech trying into are companies that own is it and of can plays Many their
business that in company initiatives. in very been productive own owners the having so, And has development pharma/biotech overall also our
any not and gross We we that of are also on does about excited really benefit. this making the include are margins Uman the progress
as again, actually once XXX. brought past. we've to commercial executive Fry our strong as I've team. two delivered our and nearly we've actually XXX margins improvement We've of recently very as the and basis three half, And for points a it's CFO. point gross is Counsel, scale basis But first it as in continued General Amol in brought Amol, in with our We leaders, of working lot had John the in well key which experience a XXX
real in were the to We was which acquired a third for Uman our cash a preservation. stock, productively about very nice use we that able and benefit paid of consideration
also really feeling ahead launching our of We as did schedule, as a early, productive launches launched HD-X part and their around we SP-X. announce well of and important that it's were as growth a Both an we the little company. were continued them of are
also just about team. personnel from were into We very able global of to months those moved acquisition the XXX,XXX cost-efficient foot. all the our We Uman a square with from Quanterix headquarters, combine ago XX almost
center all disruption and in together for We are biomarker this now innovation.
that. excited So about pretty
at we had biomarkers showing going are where neurology it a approval, Conference. use even ran drug a of session We panel of most discussion was conferences using buzz that top is these dinner a possibility I potentially, to rescue. at strong and around had as the and a the really the a recent company moderated helping standing-room of we in where only I had that leaders. also there We then for summary a thought now we Alzheimer gave four and actually
an peer-reviewed about talk to publications, a that of coming just of bit be moment. ECTRIMS lot our more continued important is in have The a to next up big to also And advance. be part we'll one a third-party going It's in we've which Stockholm. continues and
the And that you'll But we that, was is and look from overall hear above this a most of our a be Amol. growth more next more illustrates this you notable revenue side, when and that's bit once top-line right-hand expect would level continuing the again is the little of very breakdown slide average growth here level at strong consumable what's that we that overall of that, growth. say will XX% trajectory
increased quarter And really this where is, been I of in a driving third catalyst consumer quarter our row that as or new strong growth well instruments, placing we've as think, growth, – the utilization fourth of very a fourth instruments.
again As growth this quarter. see, you instrument we've can got
maybe flat translates growth. or are very into third growth growth really we instruments good which our later years launching consecutive were at placing of consumables, after quarter I forward-leading volume, a since which regulated having now that's and three think platforms, pace see We nice to on potentially fourth starting these consecutive in indicator. instrument basically catalysts the newer of is a
really leading services we But That's trying stay studies because a lab you been ultimately then this saw they we and also services see level our technology. also well growth. growing strong and We always at recovery the that, really many indicator our of do We've are as parameter had lab those and a XX% quarter. can to of that buy use our there.
of a business. So component very our profitable, promotional that we've made
drugs. we opposite for we the downstream our lot instrument as of are services yielding also And pharma lab ultimately diagnostics a looking offering and making for exploring margins to continue drug opportunities make services. where to evolve on it's But companion our lot a are ways patient then, We great approvals placements. those it's performance of monitoring
almost triple-digit. nearly and in margin has that opportunity growth to represents our services business We then the it note you biggest and for at actually is half evolve can And is the company gross has we of interesting to lab now, strategically of that half out. got as that our half play is the continue the see consumables first bottom, going of consumables that to been feel think I first lot where a our
path cancer they symptoms particularly, is, everyone, a at So, very diseases. we don't overall company have very are in and look discover just that by the it lethal that neurodegeneration, as are industry to these is time and there the in when late-stage until are and today, have you to the you symptoms you healthcare disease the remind diagnose
A the But now using a our have invasiveness. on technologies high-level going axis the right-hand the our is that lot able earlier, this being we to premise exquisite of just on next explore Y less much the by slide. disease sensitivity we're past. slide used in you that in see and to further shows we've side invasively It's of much the
and infections spinal cerebral I sick, think a even that painful very never taps, are so, spinal these patients will and you very to invasive when - invasiveness are reduce biopsies and cerebral actually from allow you them most create and expensive spinal and tap. even can taps As they take
Cerebral on technologies health the CSF, the the very most are Fluid what procedure that's that left invasive highly today approaches. head is red in see a to can diagnostics of in see, invasive so today's So, the why Spinal and in it’s box area the
saliva you X detect then disease blood you Now when on axis, and see the can it? do at the the bottom and
long that boxes allows It's and diagnostics up longer-term neurodegeneration. less with and company. red detection to cancers the what we capabilities. moving blue you start this game-changer our Again, and invasiveness into is cancer is And it symptoms does are after The today's area believe earlier much for that creation of sensitivity a picking better to is cost. this neuro value and us a the slide
joined, deploying. we've a next four where and roadmap slide is been regulatory years what four-and-a-half said So systematic research We when and of no of I let's about there diagnostics ago is ago risk. the moved out actually reimbursement redeploy years
for technology lot in publication these and third-party validation of Let's the research establish and a peer-reviewed publications markets.
started, can much believe be by before, to was XX can this diagnostics in you and research ultimately couldn't that's opportunity return opening And $X want about value around But the and numbers we that creation keep particularly into we we billion up X moving continue blood. when new a as into x market that to see that to research to diagnostics. higher biomarkers market seen actually we do evolve
with got launched And we've research on then, where products pharma and is services starting both research, we got are we've bubble into - side, neurology oncology. just we services and the second and in these the right-hand and
know can area, and You blue best-in-class the patient. to way get immunotherapies, work the therapy the research, see actually oncology acquisition we the oncology, grey be about important to on three-times we area it's of for size to early the able of a whether think is a multiplexing very either with kill great have or at through Aushon is going to where particularly now
disrupt the is on then, you is area, measure area hope largest into where where and be right, in you neurology So diagnostic the diagnostic Nf-L that's blue bubble the And decide what can of this first should of and we can in to it. lot acquisition the there plays a see total the which is taken.
just you growth. next breaking This shows and stratifying ways we the slide are down our
nicely the our estates. growing it and in and right out first most of Most are Europe – now America. our very we you company see half. for are see can in But Asia we can North those So of is growth we building
progress can the there. a working and to But we growth lesser see product hard we're increase been and then academia. standpoint, the customer-base are academia new having From we've we with XX% you good pharma are placements in
next And drive can how of that that of oncology, understand It's in of see this see really you and for leading a indicators. fight next the really oncology can the opportunity. wave neurology from metric. This finally then you XX, beginnings out is XX% now and is are for we businesses to you our all there Slide slide, which
lot that of spent we've We really to want a showcase time.
third-party validate sponsor technology. a we called the scientists inspire third-party to are Health, nonprofit am of Precision We the to founder lead studies Powering try do where and to I the
see where are second are peer-reviewed to technology. inside on actually protein can our close and and the source use want we a oncology. look are they to being they can brew a customers And the whatever deployed at the in home that times of can of want brew Many side, domination the pairs biomarkers whatever You framework. antibody we that left-hand now offer home kit then, you XXX and category third-party publications neurology see
it's pipeline a brew and what piece good We still and future big of on a a collect of of markers home lot are. have money testing profitability
ago, a represents over it company. our three value in Europe So the XX% of Nf-L, of home brew and now years was
about our we the of biomarkers publications. really about these revenue So the continuing the we XX% excited of excited with are of to increase really prospects are the company and
trials. business grow lab. that And to Aushon you number you continued the that and we we red we drug of now is accelerator, of ramp then, represents acquisition X, it into have which and up had move see and gave our And you to the can services the X, see us CLIA the that continue that Phase can X line the
the then seen sudden were the and you growth up. you can see this then growth. and that flat And we nice In can just real year. pretty and quarter we it build placements; we've XXXX for ramp now, prior by instruments it on a many see started see right consumable XXXX to the of see can the side nicely continues out years versus to all spiking And and some you then very
which different we And now SR-X the of a you instruments; and the platforms the then, see as types and five The we what Slide kit And instruments and the well assay last each sell on reminder that we can the now are of launched we assay accelerator services and next the say, we've growth. instrument on quarters, right. do the slide, of platforms We is XX, year. north HD-X and sell. have just got then kits, we razorblades SP-X sell through instruments, different last, would then of the are I the we for XX% launched
and well, talked there investors launched sensitivity, Powering next one the major need all of had slide is to for validate effects years and very of samples detection, about and well first involved for technologies Health our many able This are detection, earlier is from coupled sensitivity. we and Well then, competitors being no asked us invasive sensitivity. the Precision need scientists small have with many matrix all answers the that that with as as when benefits said, about over get got less we these eliminating
competitors significantly have three now I But has automated think, platforms. And we our so, But of our a position. slide. it, sensitivity three competition our versus then created advantage showing this exited still last dynamic four or evolved are into and range And years. multiplexing then our are over moving with also we multiple we the
advantages. how still this are see have can how continue platforms going those our to competitive we you major to advantages. evolves and evolve that So And
goals see next of can to the set on half, first most of XXXX basically slide, establish. which you of a advanced where this that we ahead into As were schedule. we we've By place at the that is we going going the way goals these are end actually
So neurology penetration. we're really excited our about
excited expectations. are financials, only also but in continuing our not growth we've the pursue XXX then of margins of we'll then beginnings in about penetration the oncology plus in of a strategically third-party technology, top-line, acquiring to a talk had ahead are gross continuing of our x we original the to lot And the our advance. about. with SP-X, the validation have We Nf-L, Uman, And on
it of slide The pharma. our next sense you makes about compelling gives what to technology is that a it
side, can that drugs. efficacy efficacy you is today's cancer, left huge the see probability talking that to levels going toxicity for and issues are very many you drug the low of done work. Over particularly, of for And are about
Alzheimer it's of been neurology, as There even approved progression at that an alters in this point. disease bad. really just drug the And area hasn't
itself and get So, probability when you X a increase from XXX% based a approval. estimates our is technology and Phase a increase you use pharma approval, you'll there the that on of X biotech Phase get
are XX we right-side utilizing with are rapid as saying, see be actually we encourage and the going to more drugs providing be on and well dosing, less The Slide LabCorps the can you if biomarkers. on that Medicine. Quests, approved now effective FDA, of get guidance our get you technologies, These others is And the them Rules-Based see the with think via earlier to ramp makes use biomarkers technology to disease out they safer, CROs. approved as the you because drugs which to you can the are can
just base distribution have slide now for broad Precision customers shows we last the used up And selling. and Powering of ramped our the over next to of many most come those give Health – opportunity has very those and referenced to customers installed our how us couple years Summit of rapidly a cases, the
This just Companies creating into interest a got like next primarily slide are you that you primarily, the lot research from have markets. – It's have launched a a the validity standpoint a when Illumina playing analytical there that, of of and shows excitement. and are today. is research biomarker that we of lot in markets and XXX%
to going peer-reviewed blood one key move the right in validation effectively FDA. is and clinical left to it see only get with and we you and that of a that repeatably third-party, and of with from up, can working as right, one to move But that that Nf-L of are happens markers and ones be your really go the lot validity the the we're keep markers we to the value the the trying to
using it and to the up multiple eclipse XX this is And on point. next presentations ECTRIMS in active were for see with the of primarily right spring growing the see coming is Stockholm, would side Nf-L, further the companies I ECTRIMS, lot you sclerosis going which trials you slide, one, that publications can on the are astronomically now next utilizing see right-hand at a and of Nf-L can number the you expect in
and those evidence only and about using But neuro in XXX% But might have are our next publications publications. blood, measuring Most find Simoa you just that's that in a you'll then, and publications you in if blood total so when there many at is of way the the how many utilized the that XXX of other pairs look you Uman's shows be of The look slide antibody to at diseases. publications it that are Nf-L, Uman's out using acquisition. can are you Nf-L. by key also CSF
of other trying could that stands to years to that, you pairs. you Uman's and spent those pairs look up blood places we antibody from at redacted Uman with when and all looked antibody see for And the we three apart can come CSF, relate that
us what's on look shots the exciting really next so, focus. when see for goal is, you three at for our And we current slide,
real trials there Obviously seeing $XX out Europe. is effective drugs, XX excited the that approved is about of Alzheimer's already a and based new and is of also publication beginnings to are Nf-L there but XX that, starting obviously, because out we recently before years dementia help whether disease value from be patients MS, or not on billion read was can in also that or not see drug there
TBI where currently endpoints primary have actually way. then we And under another is area
So see the is that still undiagnosed there a the continued the bad next Alzheimer in on from report obviously, there as us see blood, has patients, of is the slide, Alzheimer's interest, XX beginnings is as by front, able on Biogen being But aducanumab. million Nf-L. to of been there CNN and you on mentioned news can there lot
on beta-amyloid, first that amyloid way of curve kind and also which think we early under that a can area in But technology, of XX% beta the disease we've non-invasive on, really see someday cycle. provide phase very amyloidosis it got
in companies lot of a time. there represent can drugs, later actually conference, next and has a believe like drugs recent many after the slide anti-beta-amyloids still Alzheimer of we actually for at biomarkers been these So see the a Eisai but at platform failed that we used going rescuing you
deeper get do So, little to to bit now the over like what a financials. to I'd it Amol? Amol is into turn
